US · Healthcare · Biotechnology
EPS came in at 1.22 against a street estimate of 1.76 — a miss of 30.6%.
Analysts rate Halozyme Therapeutics Inc a buy (4 buy, 3 hold, 1 sell out of 8) with an average price target of $86.89.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.18% |
| Vanguard Capital Management, LLC | 4.44% |
| Vanguard Portfolio Management, LLC | 4.43% |
| State Street Corp | 4.16% |
| Amvescap Plc. | 3.38% |
| Bank of America Corp | 2.46% |
| Boston Partners Global Investors, Inc | 2.26% |
| Morgan Stanley - Brokerage Accounts | 2.16% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-07-02 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Results announced · Q2 2026 | 2026-05-11 |
| Shareholder vote results · Q2 2026 | 2026-05-07 |
| Board / officer change · Q2 2026 | 2026-04-30 |
| Proxy statement · Q4 2025 | 2026-03-23 |
| Annual report FY2025 | 2026-02-17 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2026 financial guidance and 2025 preliminary revenue estimates provided Halozyme Therapeutics released preliminary 2025 financial estimates on January 28, 2026. The company projects 2025 total revenue between $1,385-$1,400 million, consisting of: royalties ($865 | 2026-01-28 |
| Entered into merger agreement to acquire Elektrofi, Inc. Halozyme Therapeutics announced on September 30, 2025 that it is acquiring Elektrofi, Inc. for $750 million in upfront cash payment, plus up to $150 million in additional milestone payments | 2025-10-03 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Halozyme Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.